Table 2.
Rodent glimepiride treatments in previous publications.
| Species | Strain | Glimepiride (mg/kg/day) | Route of administration | Length of treatment | Blood glucose | Reference |
|---|---|---|---|---|---|---|
| Mouse | ApoE−/− | 0.1 | Oral gavage | 8 weeks | Decreased | [40] |
| KK-Ay | 0.5 | Oral gavage | 8 weeks | Decreased | [41] | |
| C57Bl/6 | 2 | Oral gavage | 4 weeks | Decreased | [42] | |
| db/db/C57Bl/6 + STZ | 2.5 | Oral gavage | 6 weeks | Decreased | [43] | |
| KsJ-db/db | 2.5 | Oral gavage | 4 weeks | Decreased | [44] | |
| BALB/c | 4 | i.p. | 3 weeks | Decreased | [45] | |
| Swiss albino + STZ | 10 | Oral gavage | 1 week | Decreased | [46] | |
|
| ||||||
| Rat | OLETF | 0.05 | Chow add-mixture | 12 weeks | Unchanged | [47] |
| Wistar ± STZ | 0.09 | Oral gavage | <1 day | Decreased | [48] | |
| Wistar | 0.1 | Drinking water | 4 weeks | n.d. | [32] | |
| Sprague-Dawley | 4 | Oral gavage | 3 days | n.d. | [49] | |
| Wistar | 5 | i.p. | 2 days | Unchanged | [50] | |
| ZDF | 5 | Oral gavage | 12 weeks | Unchanged | [36] | |
| BB | 200 | Oral gavage | 108 days | Decreased | [51] | |
| Wistar ± STZ | 200 | Oral gavage | 3 days/8 weeks | Decreased | [52] | |
i.p. = intraperitoneal injection; n.d. = not determined; OLETF = Otsuka Long-Evans Tokushima fatty; STZ = streptozotocin; ZDF = Zucker diabetic fatty.